Bubendorf, Switzerland, Tuesday, September 2, 2015 – CIS Pharma has engaged in a research program to develop a new technology platform that creates water-soluble formulations of highly hydrophobic drugs. The approach comprises a polymer-based solubilization technology that can be applied to a large number of water-insoluble drugs. The technology aims to improve the bioavailability and tolerance for drugs used in various indications such as in the ophthalmic field. The lead polymers are based on the Cellophil® Smart Polymer platform and are customized to specific drugs, site of delivery and pharmaceutical activity.

About Cellophil

Cellophil® is a platform of polymers that are based on natural amino acids linked to acrylics. The platform polymers show excellent biocompatibility, superior to the polymers most commonly used in the implant and drug-delivery industry. The safety of Cellophil® polymers has been demonstrated: no cytotoxic, allergic or hemolytic potential was observed. And it was also shown that the specific structures of Cellophil® Smart Polymers offer a good environment for cellular attachment. The patented Cellophil Smart Polymers comprise unique structures providing ideal contact points for the attachment and the delivery of therapeutics. Cellophil® is loaded with active compounds, from small molecules up to large protein-based drugs. The release kinetic of the immobilized therapeutics is varied using different linker chemistry.

About CIS Pharma AG

CIS Pharma AG is an innovator in the life science industry. The company was founded in 1952 and is family owned. CIS Pharma is located in the life science cluster of Basel, Switzerland. In our laboratories, we synthesize novel molecules, develop new biomaterials and create cutting-edge medical devices. Our mission is to improve the risk-benefit profile of currently used medical treatments. For more information about the company, visit our website www.cis-pharma.com. — Discovery is our business, progress our passion.